Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Speakers include moderator John James, founder of Innovate Arkansas client firm Acumen Brands; Carl Tannenbaum, chief economist at Northern Trust; John Silvia, the managing director and chief economist for Wells Fargo and Kathy Deck, director of the CBER.
InterveXion Therapeutics LLC, a University of Arkansas for Medical Sciences BioVentures startup company, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.
The firms making the announcement with Gov. Asa Hutchinson from downtown Conway were Metova Inc., of Franklin, Tennessee; Atlanta-based Big Cloud Analytics; and Conway's Eyenalyze.
The Northwest Arkansas Council announced a three-year development plan for the region at its winter meeting Tuesday in Rogers.